Logo image of MTVA

METAVIA INC (MTVA) Stock Fundamental Analysis

USA - NASDAQ:MTVA - US64132R4048 - Common Stock

0.9751 USD
+0.01 (+0.86%)
Last: 10/28/2025, 5:20:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MTVA. MTVA was compared to 534 industry peers in the Biotechnology industry. MTVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MTVA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MTVA has reported negative net income.
In the past year MTVA has reported a negative cash flow from operations.
In the past 5 years MTVA always reported negative net income.
In the past 5 years MTVA always reported negative operating cash flow.
MTVA Yearly Net Income VS EBIT VS OCF VS FCFMTVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of MTVA (-100.17%) is worse than 75.66% of its industry peers.
MTVA has a worse Return On Equity (-192.13%) than 66.10% of its industry peers.
Industry RankSector Rank
ROA -100.17%
ROE -192.13%
ROIC N/A
ROA(3y)-88.7%
ROA(5y)-125.52%
ROE(3y)-162.29%
ROE(5y)-200.75%
ROIC(3y)N/A
ROIC(5y)N/A
MTVA Yearly ROA, ROE, ROICMTVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

MTVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTVA Yearly Profit, Operating, Gross MarginsMTVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

MTVA has more shares outstanding than it did 1 year ago.
MTVA has more shares outstanding than it did 5 years ago.
MTVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MTVA Yearly Shares OutstandingMTVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MTVA Yearly Total Debt VS Total AssetsMTVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -12.26, we must say that MTVA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MTVA (-12.26) is worse than 76.78% of its industry peers.
There is no outstanding debt for MTVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.26
ROIC/WACCN/A
WACCN/A
MTVA Yearly LT Debt VS Equity VS FCFMTVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 2.08 indicates that MTVA has no problem at all paying its short term obligations.
With a Current ratio value of 2.08, MTVA is not doing good in the industry: 73.60% of the companies in the same industry are doing better.
A Quick Ratio of 2.08 indicates that MTVA has no problem at all paying its short term obligations.
MTVA has a worse Quick ratio (2.08) than 72.10% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 2.08
MTVA Yearly Current Assets VS Current LiabilitesMTVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.87% over the past year.
EPS 1Y (TTM)72.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MTVA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.04% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.6%
EPS Next 2Y34.76%
EPS Next 3Y21.69%
EPS Next 5Y-1.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTVA Yearly Revenue VS EstimatesMTVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 50M 100M 150M 200M 250M
MTVA Yearly EPS VS EstimatesMTVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 -5K -10K -15K -20K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MTVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTVA Price Earnings VS Forward Price EarningsMTVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTVA Per share dataMTVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

MTVA's earnings are expected to grow with 21.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.76%
EPS Next 3Y21.69%

More info and screens

0

5. Dividend

5.1 Amount

MTVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METAVIA INC

NASDAQ:MTVA (10/28/2025, 5:20:01 PM)

0.9751

+0.01 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-17 2025-11-17
Inst Owners1.11%
Inst Owner ChangeN/A
Ins Owners1.28%
Ins Owner Change1.63%
Market Cap23.60M
Revenue(TTM)N/A
Net Income(TTM)-18491000
Analysts84.44
Price Target14.03 (1338.83%)
Short Float %0.22%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.6%
Min EPS beat(2)17.77%
Max EPS beat(2)41.42%
EPS beat(4)4
Avg EPS beat(4)28.1%
Min EPS beat(4)17.77%
Max EPS beat(4)41.42%
EPS beat(8)6
Avg EPS beat(8)-6.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)27.09%
EPS NQ rev (3m)30.84%
EPS NY rev (1m)25.63%
EPS NY rev (3m)26.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.45
P/tB 2.45
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -100.17%
ROE -192.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.7%
ROA(5y)-125.52%
ROE(3y)-162.29%
ROE(5y)-200.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 2.08
Altman-Z -12.26
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)291.11%
Cap/Depr(5y)174.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.95%
EPS Next Y74.6%
EPS Next 2Y34.76%
EPS Next 3Y21.69%
EPS Next 5Y-1.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-116.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.03%
OCF growth 3YN/A
OCF growth 5YN/A

METAVIA INC / MTVA FAQ

What is the fundamental rating for MTVA stock?

ChartMill assigns a fundamental rating of 2 / 10 to MTVA.


Can you provide the valuation status for METAVIA INC?

ChartMill assigns a valuation rating of 1 / 10 to METAVIA INC (MTVA). This can be considered as Overvalued.


How profitable is METAVIA INC (MTVA) stock?

METAVIA INC (MTVA) has a profitability rating of 0 / 10.


How financially healthy is METAVIA INC?

The financial health rating of METAVIA INC (MTVA) is 5 / 10.


Can you provide the expected EPS growth for MTVA stock?

The Earnings per Share (EPS) of METAVIA INC (MTVA) is expected to grow by 74.6% in the next year.